Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.
Saved in:
| Title: | Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial. |
|---|---|
| Authors: | Dimopoulos MA; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Department of Medicine, Korea University College of Medicine, Seoul, South Korea. Electronic address: mdimop@med.uoa.gr., Schjesvold F; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway., Fu C; The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China., Hartley-Brown MA; Dana-Farber Cancer Institute, Boston, MA, USA., Gomez C; Department of Haematology, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK., Reece D; Department of Medical Oncology and Hematology, The Princess Margaret Cancer Centre, Toronto, ON, Canada., Mikala G; Department of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary., Alkharabsheh O; USA Health Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA., Parrish C; Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK., de Queiroz Crusoé E; D'Or Institute for Research and Education, Salvador, Brazil and Department of Internal Medicine, Federal University of Bahia, Salvador, Brazil., Gálvez K; Hospital Pablo Tobón Uribe, Medellín, Colombia., Idrobo H; Julián Coronel Medical Center, Cali, Colombia., White D; Division of Hematology, Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada., Gupta R; Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, New York, NY, USA., Lee C; Department of Haematology, Royal Adelaide Hospital, Adelaide, SA, Australia., Liu CJ; Division of Transfusion Medicine, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan., Quach H; Department of Haematology, St Vincent's Hospital Melbourne, University of Melbourne, Melbourne, VIC, Australia., Wang Y; Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China., Cerchione C; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy., Forsyth C; Department of Haematology, Gosford Hospital, Gosford, NSW, Australia., Hungria V; Clinica São Germano, São Paulo, Brazil., Kalaskar P; Mumbai Oncocare Centre, Thane, India., Graklanov V; Department of Clinical Hematology, University Hospital Sveti Georgi, Medical University of Plovdiv, Plovdiv, Bulgaria., Ho PJ; Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Sydney, NSW, Australia., Klaiber-Hakimi M; Clinic for Hematology, Oncology and Palliative Care, Marien Hospital Düsseldorf, Düsseldorf, Germany., Kwong YL; Division of Haematology, Oncology, and Bone Marrow Transplantation, Department of Medicine, School of Clinical Medicine, University of Hong Kong, Hong Kong Special Administrative Region, China., Louzada M; London Regional Cancer Center, London, ON, Canada., Mazumder A; The Oncology Institute of Hope & Innovation, Glendale, CA, USA., Miles O; Department of Haematology, Musgrove Park Hospital, Taunton, UK., Nagarajan C; Department of Haematology, Singapore General Hospital and National Cancer Centre Singapore, Singapore, Singapore., Prasad SVSS; Department of Hematology and Medical Oncology, Apollo Hospitals, Hyderabad, India., Raab MS; Heidelberg Myeloma Center, Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany., Varga G; Department of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary., von der Heyde E; Onkologische Schwerpunktpraxis Dres Ingo Zander und Eyck von der Heyde, Hanover, Germany., Xia Z; Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China., Ochoa PA; Instituto Alexander Fleming, Buenos Aires, Argentina., Oriol A; Catalan Institute of Oncology and Josep Carreras Institute, Hospital Germans Trias i Pujol, Badalona, Spain., Yuda J; Department of Hematology, National Cancer Center Hospital East, Chiba, Japan., Kuroda J; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan., Gong J; Bristol Myers Squibb, Princeton, NJ, USA., Zhou Z; Bristol Myers Squibb, Princeton, NJ, USA., Maciag P; Bristol Myers Squibb, Princeton, NJ, USA., Yu B; Bristol Myers Squibb, Princeton, NJ, USA., Rocci A; Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland., Koo P; Bristol Myers Squibb, Princeton, NJ, USA., Katz J; Bristol Myers Squibb, Princeton, NJ, USA., Richardson PG; Dana-Farber Cancer Institute, Boston, MA, USA. |
| Corporate Authors: | SUCCESSOR-2 Trial Investigators |
| Source: | Lancet (London, England) [Lancet] 2026 Jun 14. Date of Electronic Publication: 2026 Jun 14. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
